23965-11-9 Usage
Uses
Used in Medicinal Chemistry:
6-bromo-3-phenyl-2,4(1H,3H)-quinazolinedione is used as a pharmaceutical candidate for its anticancer properties, offering a new avenue for the development of cancer treatments. Its anti-inflammatory properties also make it a potential candidate for the treatment of inflammatory diseases.
Used in Drug Development:
As a quinazoline derivative with demonstrated biological activities, 6-bromo-3-phenyl-2,4(1H,3H)-quinazolinedione is utilized in the development of new drugs targeting various diseases, particularly those with unmet medical needs.
Used in Organic Synthesis:
6-bromo-3-phenyl-2,4(1H,3H)-quinazolinedione serves as a key intermediate in organic synthesis, contributing to the creation of a variety of chemical compounds with diverse applications.
Used as a Building Block in Synthesis:
6-bromo-3-phenyl-2,4(1H,3H)-quinazolinedione is used as a building block in the synthesis of other complex organic molecules, facilitating the development of novel chemical entities with potential applications in various fields, including pharmaceuticals, materials science, and agrochemicals.
Used in Research:
6-bromo-3-phenyl-2,4(1H,3H)-quinazolinedione is employed in research settings to explore its potential uses and properties further, with the aim of expanding its applications and understanding its mechanisms of action.
Check Digit Verification of cas no
The CAS Registry Mumber 23965-11-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,9,6 and 5 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 23965-11:
(7*2)+(6*3)+(5*9)+(4*6)+(3*5)+(2*1)+(1*1)=119
119 % 10 = 9
So 23965-11-9 is a valid CAS Registry Number.
23965-11-9Relevant academic research and scientific papers
Design, synthesis, and biological evaluation of triazolyl- and triazinyl-quinazolinediones as potential antitumor agents
Al-Romaizan, Abeer N.,Ahmed, Nesreen S.,Elfeky, Sherin M.
, (2019/03/07)
Novel 6(3-1H-1,2,4-triazol-1-yl)-3-phenylquinazoline-2,4(1H,3H)-diones (7a-e) were synthesized from different enaminones (6a-e) with 6-hydrazinyl-3-phenylquinazoline-2,4(1H,3H)-dione. 2,6(4-2-Substituted-1,3,5-triazin-1(2H)-yl)-3-phenylquinazoline-2,4(1H,3H)-diones (8a-k) were synthesized from the reaction of 1-(2,4-dioxo-3-phenyl-1,2,3,4-tetrahydroquinazolin-6-yl)thiourea, urea, or guanidine (3a-c) with enaminones (6a-e), and a series from 3-substituted-2-imino-1,3,5-triazin-1(2H)-yl-sulfonyl-phenyl-1-methylquinazoline-2,4(1H,3H)-dione (12a-j) were obtained from the reaction of N-(diaminomethylene)-4-(1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)benzenesulfonamide (11) with the enaminone (6a-j). The antitumor activity of the synthesized compounds was evaluated against two human cell lines: human colon carcinoma HCT116 and human hepatocellular carcinoma HEP-G2. Some of the tested compounds showed significant potency compared to the reference drug staurosporin.
3-aryl(alkyl)quinazoline-2,4(1H,3H)-diones and their alkyl derivatives
Shestakov,Sidorenko,Bushmarinov,Shikhaliev,Antipin
experimental part, p. 1691 - 1696 (2010/04/29)
Two-stage reaction of methyl anthranilate with aryl(alkyl) isocyanates in keeping with the quantumchemical calculations and XRD analysis resulted in 3-aryl(alkyl)quinazoline-2,4(1H,3H)-diones that by treatment with alkyl halides, phenacyl bromides, esters
